Anlon Healthcare has incorporated a subsidiary namely ‘Anlon Biologics’ on July 10, 2026. The purpose of acquisition/ incorporation of this subsidiary is aligned with the company’s long-term growth objective. Considering this subsidiary would be manufacturing surgical implants and medical devices, the company intends to leverage this opportunity in order to strategically complement and expand its existing business in the pain management segment. The company holds 65% of the share capital of Anlon Biologics that is 65,000 equity shares of face value Rs 10 each.
Earlier, the board of directors of the company at its board meeting, held on July 01, 2026, had inter alia considered and approved the same.
Anlon Healthcare is a chemical manufacturing company engaged in manufacturing of pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs), which are supplied to customers both in ndia and international markets.
